Ralph J. DeBerardinis

Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018

Metabolic reprogramming and cancer progression

Metabolism as cancer progresses Numerous cancer-specific alterations in metabolism have been identified but have not yet resulted in an effective anti cancer therapeutic. In a R...

Autophagy in metazoans: cell survival in the land of plenty

Cells require a constant supply of macromolecular precursors and oxidizable substrates to maintain viability. Unicellular eukaryotes lack the ability to regulate nutrient concen...

Supplementary Data from Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance

Supplementary Data from Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance

Supplementary Data from Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance

Supplementary Data from Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance

Supplementary Data from Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance

Supplementary Data from Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance

Supplementary Data from Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance

Supplementary Data from Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance

Supplementary Data from Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance

Supplementary Data from Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance

Supplementary Data from Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance

Supplementary Data from Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance

Supplementary Data from Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance

Supplementary Data from Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance

Supplementary Data from Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance

Supplementary Data from Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance

Supplementary Data from Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance

Supplementary Data from Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance

Supplementary Data from Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance

Supplementary Data from Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance